| | |
| Novo sees U.S. Tresiba launch 3-5 yrs after trial start Wednesday, May 01, 2013 12:03 AM PDT COPENHAGEN (Reuters) - Denmark's Novo Nordisk, the world's biggest insulin producer, said it hoped to launch its insulin Tresiba in the United States three to five years from the time it starts cardiovascular trials. The company expects to start the trials within a year. Chief Financial Officer Jesper Brandgaard also told journalists that he expected the cost of the cardiovascular trials for Tresiba to be around $200 million to $300 million over a four to five year period. U.S. ... Full Story | Top |
| Monster sues San Francisco city attorney over energy drinks probe Tuesday, Apr 30, 2013 07:01 PM PDT  By Terry Baynes (Reuters) - Monster Beverage Corp has sued San Francisco's city attorney over an investigation the city launched last year into the safety and marketing of Monster energy drinks. In the lawsuit filed on Monday in California federal court, the company accused City Attorney Dennis Herrera of violating its constitutional rights by demanding that the company reformulate its drinks and change its product labels and marketing materials. ... Full Story | Top |
| Ireland proposes limited access to abortion amid heated debate Tuesday, Apr 30, 2013 04:39 PM PDT  By Padraic Halpin DUBLIN (Reuters) - Irish government ministers agreed draft legislation on Tuesday to allow for limited access to abortion where a woman's life is in danger, including the threat of suicide, a proposal that has already divided the country's ruling coalition. Ireland's two-decade-old debate over how the government should deal with a Supreme Court ruling that abortion be permitted when a woman's life was at risk was re-opened last year following the death of a woman who was denied an abortion of her dying foetus. ... Full Story | Top |
| FDA approves Plan B for girls as young as 15 Tuesday, Apr 30, 2013 04:12 PM PDT WASHINGTON (Reuters) - The U.S. Food and Drug Administration on Tuesday said it would allow the Plan B One-Step contraceptive to be sold without a prescription to girls as young as 15 years of age. The announcement partially reverses a December 2011 decision that prevented the sale of the emergency contraceptive to all females of reproductive age, which was also overturned by a U.S. district judge in New York on April 5. The FDA said its approval was not related to the judge's ruling. ... Full Story | Top |
| Vertex posts loss, raises cystic fibrosis sales view Tuesday, Apr 30, 2013 03:39 PM PDT By Bill Berkrot (Reuters) - Vertex Pharmaceuticals Inc on Tuesday increased by $20 million the 2013 forecast for sales of its cystic fibrosis drug Kalydeco, and said it anticipates seeking approval in 2014 of a CF combination therapy that has become a focus for investors. The new cystic fibrosis drug Kalydeco had sales of $61.8 million, up from $58.5 million in the previous quarter. The company now expects 2013 Kalydeco sales of $300 million to $340 million, up from its prior view of $280 million to $320 million. ... Full Story | Top |
| California woman accused of planting poisoned juice at Starbucks Tuesday, Apr 30, 2013 03:38 PM PDT By Laila Kearney SAN FRANCISCO (Reuters) - A northern California woman has been arrested on suspicion of spiking orange juice bottles with a deadly dose of rubbing alcohol and stocking the bottles at a Starbucks coffee shop, law enforcement officials said on Tuesday. Ramineh Behbehanian, 50, was arrested at her San Jose home on Monday night and booked into the Santa Clara County Jail on charges of attempted murder and poisoning, San Jose Police Sergeant Jason Dwyer said. ... Full Story | Top |
| Questcor profit misses estimates on weak Acthar sales Tuesday, Apr 30, 2013 03:15 PM PDT (Reuters) - Questcor Pharmaceuticals Inc's first-quarter profit lagged analysts' expectations as sales of its Acthar drug fell due to Medicaid reimbursement changes but the company said sales have bounced back in the current quarter. Questcor shares fell 12 percent to $27.00 soon after markets closed but recovered to be down 2 percent at 1800 ET. The company said shipments of Acthar, which is approved to treat multiple disorders including infantile spasms, were 4,830 vials in the first quarter, down about 24 percent from the previous quarter. ... Full Story | Top |
| Boston Marathon bomb amputees offered prosthetics free of cost Tuesday, Apr 30, 2013 02:23 PM PDT  By Daniel Trotta (Reuters) - A trade group representing makers of artificial limbs on Tuesday promised to provide prosthetics free of cost to the estimated 20 to 25 victims of the Boston Marathon bombings who underwent amputations. The American Orthotic and Prosthetic Association offered initial services and prosthetics not covered by insurance for patients injured in the blasts, which tore the lower limbs off some spectators near the finish line of the race on April 15. ... Full Story | Top |
| Obama says too soon to declare demise of his domestic agenda Tuesday, Apr 30, 2013 02:03 PM PDT  By Jeff Mason WASHINGTON (Reuters) - With his fight for tighter gun control measures defeated and prospects for a deficit reduction pact dim, President Barack Obama sought on Tuesday to project an image of a leader still in control of a faltering domestic policy agenda. At a surprise news conference, Obama made the case that recent defeats did not mean he was a lame-duck leader, and said he was hopeful immigration reform would become law. ... Full Story | Top |
| Jury weighs fate of abortion doctor in murder trial Tuesday, Apr 30, 2013 01:59 PM PDT By Dave Warner PHILADELPHIA (Reuters) - A Philadelphia jury ended its first day of deliberations on Tuesday without reaching verdicts in the murder trial of a doctor accused of killing babies and a patient during late-term abortions at a clinic serving low-income women. Dr. Kermit Gosnell, 72, who ran the now-shuttered Women's Medical Society Clinic, could face the death penalty if convicted by the jury in Common Pleas Court in Philadelphia. The case focuses on whether the infants were born alive and then killed. ... Full Story | Top |
| Contaminated ground turkey found in 21 states: report Tuesday, Apr 30, 2013 01:48 PM PDT By Carey Gillam KANSAS CITY (Reuters) - Dangerous antibiotic-resistant bacteria has been found in ground turkey on U.S. grocery shelves across a variety of brands and stores located in 21 states, according to a report by a consumer watchdog organization. Of the 257 samples of ground turkey tested, more than half were found to be positive for fecal bacteria and overall, 90 percent were contaminated with one or more types of disease-causing organisms, many of which proved resistant to one or more common antibiotics, Consumer Reports found. ... Full Story | Top |
| CVS Caremark gets contract to serve 1.1 million CareFirst members Tuesday, Apr 30, 2013 01:32 PM PDT By Jessica Wohl (Reuters) - CVS Caremark Corp is set to provide pharmacy benefit and other services for 1.1 million CareFirst BlueCross BlueShield members starting next year, a deal that could represent about $1 billion in annual spending on medications and boost CVS' profit by a penny per share, an industry analyst said. The three-year contract is the latest win for CVS Caremark, which has been gaining ground with its combined approach of running retail drugstores and a pharmacy benefits management business. ... Full Story | Top |
| FDA's Deborah Autor to join drugmaker Mylan Tuesday, Apr 30, 2013 01:22 PM PDT (Reuters) - Generic drugmaker Mylan Inc said on Tuesday it hired Deborah Autor, deputy commissioner for global regulatory operations and policy at the U.S. Food and Drug Administration, to help oversee its global regulatory strategy. John M. Taylor, III, Counselor to the Commissioner, will take Autor's place at the FDA in an acting capacity as it looks for a replacement, FDA Commissioner Margaret Hamburg said in an email to staff. ... Full Story | Top |
| How much do financial interests sway researchers? Tuesday, Apr 30, 2013 12:40 PM PDT By Genevra Pittman NEW YORK (Reuters Health) - Funding from drug companies and other potential conflicts of interest did not influence the conclusions reached by researchers testing new cancer treatments over the past few years, according to a new analysis. But Dr. Aaron Kesselheim, who has looked into that issue at the Harvard School of Public Health, pointed out that other studies have shown the opposite. ... Full Story | Top |
| Europe's regulator digs in for drug data fight Tuesday, Apr 30, 2013 12:07 PM PDT By Ben Hirschler LONDON (Reuters) - The head of Europe's medicines regulator is digging in for a fight over data transparency after being stopped from releasing information on drugs from two U.S. companies by a court ruling. Defeat for the European Medicines Agency (EMA) at the hands of AbbVie and InterMune highlights a growing battle between campaigners for more openness and companies which fear it will harm their business. ... Full Story | Top |
|
No comments:
Post a Comment